Akari Therapeutics Plc (AKTX) financial statements (2021 and earlier)

Company profile

Business Address 24 WEST 40TH STREET
NEW YORK, NY 10018
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments61697934 
Cash and cash equivalents61697934 
Restricted cash and investments   00 
Receivables00    
Other undisclosed current assets11000 
Total current assets:63707934 
Noncurrent Assets
Property, plant and equipment00000 
Intangible assets, net (including goodwill)0019   
Goodwill  19   
Intangible assets, net (excluding goodwill)000   
Restricted cash and investments00    
Other undisclosed noncurrent assets  (19)   
Total noncurrent assets:00000 
TOTAL ASSETS:63707934 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15811 
Accounts payable14411 
Accrued liabilities004   
Due to related parties  3   
Other undisclosed current liabilities161627   
Total current liabilities:17213811 
Noncurrent Liabilities
Liabilities, other than long-term debt   00 
Other liabilities   00 
Other undisclosed noncurrent liabilities00011 
Total noncurrent liabilities:00011 
Total liabilities:17213822 
Stockholders' equity
Stockholders' equity attributable to parent46494113 
Common stock18181811 
Additional paid in capital8887863434 
Accumulated other comprehensive income (loss)(0)00   
Accumulated deficit(60)(57)(63)(34)(33) 
Total stockholders' equity:46494113 
TOTAL LIABILITIES AND EQUITY:63707934 

Income statement (P&L) ($ in millions)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Gross profit:(23)23(23)   
Operating expenses(4)(4)(23)(1)(2) 
Other undisclosed operating income (loss)23(23)23   
Operating loss:(4)(4)(23)(1)(2) 
Nonoperating income (expense)111(25)(0)(1) 
Foreign currency transaction gain (loss), before tax0(0)(0)   
Other nonoperating expense   (0)(1) 
Interest and debt expense(3)0(3)   
Income (loss) from continuing operations before equity method investments, income taxes:(6)6(52)(2)(3) 
Other undisclosed income (loss) from continuing operations before income taxes3(0)3   
Income (loss) from continuing operations before income taxes:(3)6(49)(2)(3) 
Income tax benefit    1 
Net income (loss) available to common stockholders, diluted:(3)6(49)(2)(2) 

Comprehensive Income ($ in millions)

3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
Net income (loss):(3)6(49)(2)(2) 
Other comprehensive loss   (2)  
Comprehensive income (loss):(3)6(49)(3)(2) 
Other undisclosed comprehensive loss, net of tax, attributable to parent(0)(0)(0)   
Comprehensive income (loss), net of tax, attributable to parent:(3)6(49)(3)(2) 

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: